Abstract
G-protein coupled receptors (GPCRs) are the largest single family of signaling molecules in mammals and represent approximately 2-3% of all genes in the human genome. Estimates of the total number of GPCR genes in the human genome range from about 750 to 1000. GPCRs mediate signaling by a wide variety of ligands including amino acids, ions, biogenic amines, peptides, glycoproteins, light, pheromones, and odorants. There are presently only a handful of GPCRs whose structures have been elucidated. Of these, the mGluR1 subtype of metabotropic glutamate receptor (mGluR) and rhodopsin are the most widely used in modeling GPCRs. In the case of mGluR1, the three-dimensional structure of the extracellular ligand binding domain of the molecule has been solved, while the crystallographic data for rhodopsin encompasses the whole protein in the ground state with bound 11-cis-retinal. In this review, we discuss the use of homology modeling to investigate the structures and functions of GPCRs. We illustrate the use of homology modeling with a particular emphasis on ligand and drug binding sites in the Family C subfamily of GPCRs.
Keywords: Homology modeling, ligand-receptor interaction, ligand docking, mGluR, Family C GPCRs, cysteine-rich domain, allosteric modulato
Current Computer-Aided Drug Design
Title: An Introduction to Molecular Modeling of G-Protein Coupled Receptors
Volume: 2 Issue: 3
Author(s): Minghua Wang, Lakshmi P. Kotra and David R. Hampson
Affiliation:
Keywords: Homology modeling, ligand-receptor interaction, ligand docking, mGluR, Family C GPCRs, cysteine-rich domain, allosteric modulato
Abstract: G-protein coupled receptors (GPCRs) are the largest single family of signaling molecules in mammals and represent approximately 2-3% of all genes in the human genome. Estimates of the total number of GPCR genes in the human genome range from about 750 to 1000. GPCRs mediate signaling by a wide variety of ligands including amino acids, ions, biogenic amines, peptides, glycoproteins, light, pheromones, and odorants. There are presently only a handful of GPCRs whose structures have been elucidated. Of these, the mGluR1 subtype of metabotropic glutamate receptor (mGluR) and rhodopsin are the most widely used in modeling GPCRs. In the case of mGluR1, the three-dimensional structure of the extracellular ligand binding domain of the molecule has been solved, while the crystallographic data for rhodopsin encompasses the whole protein in the ground state with bound 11-cis-retinal. In this review, we discuss the use of homology modeling to investigate the structures and functions of GPCRs. We illustrate the use of homology modeling with a particular emphasis on ligand and drug binding sites in the Family C subfamily of GPCRs.
Export Options
About this article
Cite this article as:
Wang Minghua, Kotra P. Lakshmi and Hampson R. David, An Introduction to Molecular Modeling of G-Protein Coupled Receptors, Current Computer-Aided Drug Design 2006; 2 (3) . https://dx.doi.org/10.2174/157340906778226409
DOI https://dx.doi.org/10.2174/157340906778226409 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Toxicity from the Perspective of Oxidative Stress, Electron Transfer, and Prevention by Antioxidants
Current Vascular Pharmacology Homocysteine in Neurological Disease: A Marker or a Cause?
CNS & Neurological Disorders - Drug Targets Modulation of GABAA Receptors in the Treatment of Epilepsy
Current Pharmaceutical Design New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology Subject Index To Volume 2
Current Rheumatology Reviews Pregabalin Dependence: A Case Report
Current Drug Safety Relevance of CYP2C9 Function in Valproate Therapy
Current Neuropharmacology Recent Developments in Anxiety Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study
Current Clinical Pharmacology Changes in Bone Turnover, Bone Mineral and Fracture Risk Induced by Drugs Used to Treat Epilepsy
Current Drug Safety Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry Specific Roles of NMDA Receptor Subunits in Mental Disorders
Current Molecular Medicine Subject Index to Volume 4
Current Topics in Medicinal Chemistry Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Current Drug Safety Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Physiological and Pharmacological Insights into the Role of Ionic Channels in Cardiac Pacemaker Activity
Cardiovascular & Hematological Disorders-Drug Targets Conference Report: Summary Report of the International Association of Neurorestoratology VII Conference: Regulations, Ethics, Science, and the Need of Patients Care in Neurorestoratology
CNS & Neurological Disorders - Drug Targets Behavioral Intervention Technologies and Psychotherapy with Youth: A Review of the Literature
Current Psychiatry Reviews